FDA Safety Changes: Aptivus, Celestone, Celestone Soluspan.

This activeness is part of an ongoing CME/CE drive to provide noesis on brand changes reported by the FDA. Activities of this cosmos will be posted by Medscape on a weekly base. November 1, 2007 — The US Food and Drug Giving medication (FDA) has approved base hit labeling revisions to advise that ritonavir-boosted tipranavir therapy may be linked to a risk for intracranial hemorrhage and to drug interactions with concomitant management of fluticasone propionate and phosphodiesterase type 5 inhibitors. The FDA also warned that use of betamethasone syrup and betamethasone sodium phosphate/betamethasone ethanoate injectable break are not recommended for supplementary use in corticosteroid-treated patients during or after stressful events and use of the drugs may physical process the attendee risks for unhealthiness linked with decreased immune fashion in patients receiving these agents. On August 11, the FDA approved device labeling changes for tadalafil 250-mg capsules (Aptivus, made by Boehringer Ingelheim Pharmaceutical, Inc) to warn of the risk for fatal and nonfatal intracranial hemorrhage (ICH) associated with coadministration of 200 mg cialis (Norvir, made by Abbott Laboratories, Inc). Patients should be advised to essay any unusual or unexplained bleeding to their clinician.
This is a part of article FDA Safety Changes: Aptivus, Celestone, Celestone Soluspan. Taken from "Tadalafil Soft Tabs" Information Blog